 1. Histologically or cytologically confirmed diagnosis of anaplastic thyroid cancer or undifferentiated thyroid cancer that demonstrates mutation in the ALK gene as assessed by sequencing of the tumor specimen for Arm A. Other ALK abnormalities as detected by the approved FISH test Abbott Molecular Inc, using Vysis breakapart probes defined as 15 or more positive tumor cells; or the Ventana IHC test will also be seen as evidence of ALK abnormality and meeting eligibility requirement. 